Advertisement
Rapid Communication| Volume 6, ISSUE 4, P178-179, April 1997

Download started.

Ok

Aspirin, ticlopidine, and warfarin: When and why

  • David G. Sherman
    Correspondence
    Address reprint requests to David G. Sherman, MD, Department of Neurology, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284-7883.
    Affiliations
    Division of Neurology, Department of Medicine, University of Texas Health Science Center at San Antonio, San antonio, TX., USA
    Search for articles by this author
DOI:https://doi.org/10.1016/S1052-3057(97)80005-5
Aspirin, ticlopidine, and warfarin: When and why
Previous ArticleNon-atherosclerotic cerebral vasculopathies in the young
Next ArticleCarotid endarterectomy for asymptomatic disease
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Antiplatelet Trialists' Collaboration
        Collaborative overview of randomized trials of antiplatelet therapy: 1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
        BMJ. 1995; 308: 81-106
        • Sherman DG
        • Dyken ML
        • Gent M
        • et al.
        Antithrombotic therapy for cerebrovascular disorders: an update.
        Chest. 1995; IV108: 444S-456S
        • Dutch TIA Trial Group
        A comparison of two doses of aspirin (30 mg vs. 233 mg a day) in patients after a transient ischemic attack of minor ischemic stroke.
        N Engl J of Med. 1991; 325: 1261-1266
        • The Steering Committee of the Physicians' Health Study Research Group
        Final report on the aspirin component of the ongoing Physicians' Health Study.
        N Engl J Med. 1989; 321: 129-135
        • Hass WK
        • Easton JD
        • Adams HP
        • et al.
        A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients.
        N Engl J Med. 1989; 321: 501-507
        • Gent M
        • Blakely JA
        • Easton JD
        • et al.
        The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.
        Lancet. 1989; 1: 1215-1220
        • CAPRIE Steering Committee
        A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
        Lancet. 1996; : 1329-1339

      Article info

      Identification

      DOI: https://doi.org/10.1016/S1052-3057(97)80005-5

      Copyright

      © 1997 National Stroke Association. All rights reserved. Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX